Academic Journals Database
Disseminating quality controlled scientific knowledge

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?

ADD TO MY LIST
 
Author(s): Antoniu Sabina A

Journal: Multidisciplinary Respiratory Medicine
ISSN 2049-6958

Volume: 7;
Issue: 1;
Start page: 41;
Date: 2012;
Original page

Keywords: Basic fibroblast growth factor | Idiopathic pulmonary fibrosis | Inhibitor | Platelet derived-growth factor | Tyrosine kinase | Vascular endothelial growth factor

ABSTRACT
Abstract Idiopathic pulmonary fibrosis is a rare, life threatening disease characterized by an anarchic fibrogenesis, limited survival and few therapeutic options. Its pathogenesis is complex and involves the interaction among various pathways driven by proinflammatory/profibrogenetic mediators such as platelet -derived growth factor, vascular endothelial growth factor or basic fibroblast growth factor. Given their prominent pathogenic roles in this disease such growth factor might be suitable therapeutic targets.In fact, the existing preclinical and clinical data demonstrated that their therapeutic inhibition results in a delayed progression of the pulmonary fibrosis and in the improvement of the disease outcome. BIBF 1120 is a potent triple blocker of the receptors of these growth factors which is currently evaluated as a potential therapy in the idiopathic pulmonary fibrosis. This review discusses the existing data supporting its potential use in this disease.
RPA Switzerland

RPA Switzerland

Robotic process automation

    

Tango Rapperswil
Tango Rapperswil